Capital International Investors Ventyx Biosciences, Inc. Transaction History

Capital International Investors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.31 - $5.59 $6.68 Million - $16.2 Million	2,893,497 Added 122.91%	5,247,646 $12.1 Million
Q4 2023 Feb 13, 2024	SELL	$2.08 - $31.18 $777,302 - $11.7 Million	-373,703 Reduced 13.7%	2,354,149 $5.81 Million
Q2 2023 Aug 11, 2023	BUY	$28.53 - $39.55 $9.99 Million - $13.8 Million	350,068 Added 14.72%	2,727,852 $89.5 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $7.76 Million - $12.3 Million	263,040 Added 12.44%	2,377,784 $79.7 Million
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $51.1 Million - $76.9 Million	2,114,744 New	2,114,744 $69.3 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.